Herceptin Seen as Effective and Cost-Effective for ‘Worst-Case’ Early Breast Cancers in Study

Herceptin Seen as Effective and Cost-Effective for ‘Worst-Case’ Early Breast Cancers in Study
Depending on the disease characteristics and age of a women with early stage but aggressive breast cancer, the cost-effectiveness of Herceptin (trastuzumab) may vary widely, according to a recent study by researchers in New Zealand. The results were reported in “Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *